We are live on ! Find out more
SLNO

Soleno Therapeutics

Delisted

SLNO was delisted on the 15th of May, 2026.

98 hedge funds and large institutions have $1.52B invested in Soleno Therapeutics in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

314% more call options, than puts

Call options by funds: $17.1M | Put options by funds: $4.14M

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

150% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 16

29% more funds holding

Funds holding: 7698 (+22)

20% more capital invested

Capital invested by funds: $1.27B → $1.52B (+$253M)

6.33% more ownership

Funds ownership: 103.15%109.48% (+6.3%)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
98
Holders Change
+22
Holders Change %
+28.95%
% of All Funds
1.41%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
32
Increased
40
Reduced
16
Closed
10
Calls
$17.1M
Puts
$4.14M
Net Calls
+$13M
Net Calls Change
+$14.5M
Name Holding Trade Value Shares
Change
Change in
Stake
CSS
101
Cubist Systematic Strategies
Connecticut
-$2.29M -57,006 Closed
Dimensional Fund Advisors
102
Dimensional Fund Advisors
Texas
-$835K -20,754 Closed
AIC
103
AWM Investment Company
New York
-$805K -20,000 Closed
Bank of New York Mellon
104
Bank of New York Mellon
New York
-$400K -9,936 Closed
AI
105
Atom Investors
Texas
-$356K -8,846 Closed
EGM
106
Engineers Gate Manager
New York
-$310K -7,702 Closed
CAPTRUST Financial Advisors
107
CAPTRUST Financial Advisors
North Carolina
-$244K -6,058 Closed
Simplex Trading
108
Simplex Trading
Illinois
-$190K -4,192 Closed

SLNO Hedge Fund Activity: Q1 2024 in Review

98 of the 6,948 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2024, worth a combined $1.52B — up 20% from $1.27B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SLNO positions and 10 closed out — a net gain of 22 holders — while 40 added to existing stakes and 16 trimmed.

The largest buyer was Carlyle Group, adding an estimated $54.9M. The largest seller was Balyasny Asset Management, cutting an estimated $35.1M.

  • 98 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2024, up from 76 in Q4 2023.
  • Funds reported $1.52B of Soleno Therapeutics stock for Q1 2024, up 20% quarter-over-quarter.
  • 32 funds opened new Soleno Therapeutics positions in Q1 2024 and 10 closed out, a net change of +22 holders.
  • The largest Soleno Therapeutics buyer in Q1 2024 was Carlyle Group, an estimated $54.9M added.
  • The largest Soleno Therapeutics seller in Q1 2024 was Balyasny Asset Management, an estimated $35.1M sold.

Based on aggregated 13F filings for Q1 2024.